NASDAQ:TXG

10x Genomics Competitors

$194.64
+4.40 (+2.31 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$186.65
Now: $194.64
$194.96
50-Day Range
$141.09
MA: $173.75
$197.24
52-Week Range
$62.70
Now: $194.64
$201.70
Volume504,400 shs
Average Volume779,952 shs
Market Capitalization$21.17 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.39

Competitors

10x Genomics (NASDAQ:TXG) Vs. ILMN, A, MTD, WAT, AVTR, and BIO

Should you be buying TXG stock or one of its competitors? Companies in the industry of "analytical instruments" are considered alternatives and competitors to 10x Genomics, including Illumina (ILMN), Agilent Technologies (A), Mettler-Toledo International (MTD), Waters (WAT), Avantor (AVTR), and Bio-Rad Laboratories (BIO).

Illumina (NASDAQ:ILMN) and 10x Genomics (NASDAQ:TXG) are both large-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, earnings, valuation, risk and analyst recommendations.

Volatility and Risk

Illumina has a beta of 1.14, suggesting that its share price is 14% more volatile than the S&P 500. Comparatively, 10x Genomics has a beta of 1.39, suggesting that its share price is 39% more volatile than the S&P 500.

Valuation & Earnings

This table compares Illumina and 10x Genomics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Illumina$3.54 billion16.61$1.00 billion$6.5761.40
10x Genomics$245.89 million86.09$-31,250,000.00($0.80)-243.30

Illumina has higher revenue and earnings than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than Illumina, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

90.0% of Illumina shares are held by institutional investors. Comparatively, 68.8% of 10x Genomics shares are held by institutional investors. 0.4% of Illumina shares are held by insiders. Comparatively, 13.3% of 10x Genomics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Illumina and 10x Genomics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Illumina19.70%15.93%10.09%
10x Genomics-51.27%-19.98%-14.38%

Analyst Recommendations

This is a breakdown of current ratings and target prices for Illumina and 10x Genomics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Illumina48602.11
10x Genomics01702.88

Illumina currently has a consensus target price of $370.5789, indicating a potential downside of 8.13%. 10x Genomics has a consensus target price of $181.4444, indicating a potential downside of 6.78%. Given 10x Genomics' stronger consensus rating and higher possible upside, analysts plainly believe 10x Genomics is more favorable than Illumina.

Summary

Illumina beats 10x Genomics on 8 of the 14 factors compared between the two stocks.

Agilent Technologies (NYSE:A) and 10x Genomics (NASDAQ:TXG) are both large-cap computer and technology companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, valuation, profitability, risk, dividends, earnings and institutional ownership.

Volatility & Risk

Agilent Technologies has a beta of 1.04, meaning that its stock price is 4% more volatile than the S&P 500. Comparatively, 10x Genomics has a beta of 1.39, meaning that its stock price is 39% more volatile than the S&P 500.

Profitability

This table compares Agilent Technologies and 10x Genomics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Agilent Technologies13.47%21.02%10.73%
10x Genomics-51.27%-19.98%-14.38%

Institutional & Insider Ownership

68.8% of 10x Genomics shares are held by institutional investors. 13.3% of 10x Genomics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of current ratings and price targets for Agilent Technologies and 10x Genomics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Agilent Technologies081902.70
10x Genomics01702.88

Agilent Technologies presently has a consensus target price of $104.70, indicating a potential downside of 20.63%. 10x Genomics has a consensus target price of $181.4444, indicating a potential downside of 6.78%. Given 10x Genomics' stronger consensus rating and higher possible upside, analysts plainly believe 10x Genomics is more favorable than Agilent Technologies.

Valuation and Earnings

This table compares Agilent Technologies and 10x Genomics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Agilent Technologies$5.34 billion7.53$719 million$3.2840.22
10x Genomics$245.89 million86.09$-31,250,000.00($0.80)-243.30

Agilent Technologies has higher revenue and earnings than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than Agilent Technologies, indicating that it is currently the more affordable of the two stocks.

Summary

Agilent Technologies beats 10x Genomics on 8 of the 14 factors compared between the two stocks.

10x Genomics (NASDAQ:TXG) and Mettler-Toledo International (NYSE:MTD) are both large-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, profitability, institutional ownership and earnings.

Analyst Ratings

This is a summary of current ratings for 10x Genomics and Mettler-Toledo International, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
10x Genomics01702.88
Mettler-Toledo International35101.78

10x Genomics presently has a consensus price target of $181.4444, suggesting a potential downside of 6.78%. Mettler-Toledo International has a consensus price target of $971.3750, suggesting a potential downside of 20.54%. Given 10x Genomics' stronger consensus rating and higher possible upside, research analysts clearly believe 10x Genomics is more favorable than Mettler-Toledo International.

Profitability

This table compares 10x Genomics and Mettler-Toledo International's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
10x Genomics-51.27%-19.98%-14.38%
Mettler-Toledo International19.36%144.89%21.11%

Institutional & Insider Ownership

68.8% of 10x Genomics shares are owned by institutional investors. Comparatively, 93.2% of Mettler-Toledo International shares are owned by institutional investors. 13.3% of 10x Genomics shares are owned by company insiders. Comparatively, 3.2% of Mettler-Toledo International shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares 10x Genomics and Mettler-Toledo International's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
10x Genomics$245.89 million86.09$-31,250,000.00($0.80)-243.30
Mettler-Toledo International$3.01 billion9.48$561.11 million$22.7753.69

Mettler-Toledo International has higher revenue and earnings than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than Mettler-Toledo International, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

10x Genomics has a beta of 1.39, meaning that its share price is 39% more volatile than the S&P 500. Comparatively, Mettler-Toledo International has a beta of 1.04, meaning that its share price is 4% more volatile than the S&P 500.

Summary

Mettler-Toledo International beats 10x Genomics on 8 of the 14 factors compared between the two stocks.

Waters (NYSE:WAT) and 10x Genomics (NASDAQ:TXG) are both large-cap computer and technology companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, institutional ownership, earnings and analyst recommendations.

Earnings & Valuation

This table compares Waters and 10x Genomics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Waters$2.41 billion7.92$592.20 million$8.9934.16
10x Genomics$245.89 million86.09$-31,250,000.00($0.80)-243.30

Waters has higher revenue and earnings than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than Waters, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

91.8% of Waters shares are owned by institutional investors. Comparatively, 68.8% of 10x Genomics shares are owned by institutional investors. 1.5% of Waters shares are owned by company insiders. Comparatively, 13.3% of 10x Genomics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Waters and 10x Genomics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Waters48101.77
10x Genomics01702.88

Waters currently has a consensus price target of $224.20, suggesting a potential downside of 27.00%. 10x Genomics has a consensus price target of $181.4444, suggesting a potential downside of 6.78%. Given 10x Genomics' stronger consensus rating and higher possible upside, analysts plainly believe 10x Genomics is more favorable than Waters.

Volatility and Risk

Waters has a beta of 0.97, meaning that its stock price is 3% less volatile than the S&P 500. Comparatively, 10x Genomics has a beta of 1.39, meaning that its stock price is 39% more volatile than the S&P 500.

Profitability

This table compares Waters and 10x Genomics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Waters22.61%-349.31%21.11%
10x Genomics-51.27%-19.98%-14.38%

Avantor (NYSE:AVTR) and 10x Genomics (NASDAQ:TXG) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, dividends, valuation, risk, institutional ownership, analyst recommendations and earnings.

Volatility & Risk

Avantor has a beta of 1.84, meaning that its share price is 84% more volatile than the S&P 500. Comparatively, 10x Genomics has a beta of 1.39, meaning that its share price is 39% more volatile than the S&P 500.

Institutional and Insider Ownership

84.8% of Avantor shares are held by institutional investors. Comparatively, 68.8% of 10x Genomics shares are held by institutional investors. 1.9% of Avantor shares are held by insiders. Comparatively, 13.3% of 10x Genomics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Avantor and 10x Genomics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Avantor$6.04 billion3.02$37.80 million$0.5854.71
10x Genomics$245.89 million86.09$-31,250,000.00($0.80)-243.30

Avantor has higher revenue and earnings than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than Avantor, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Avantor and 10x Genomics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Avantor021402.88
10x Genomics01702.88

Avantor presently has a consensus price target of $29.7941, suggesting a potential downside of 6.10%. 10x Genomics has a consensus price target of $181.4444, suggesting a potential downside of 6.78%. Given Avantor's higher probable upside, analysts plainly believe Avantor is more favorable than 10x Genomics.

Profitability

This table compares Avantor and 10x Genomics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Avantor2.21%44.58%6.85%
10x Genomics-51.27%-19.98%-14.38%

Summary

Avantor beats 10x Genomics on 11 of the 13 factors compared between the two stocks.

10x Genomics (NASDAQ:TXG) and Bio-Rad Laboratories (NYSE:BIO) are both large-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, institutional ownership and valuation.

Risk & Volatility

10x Genomics has a beta of 1.39, indicating that its share price is 39% more volatile than the S&P 500. Comparatively, Bio-Rad Laboratories has a beta of 0.83, indicating that its share price is 17% less volatile than the S&P 500.

Institutional & Insider Ownership

68.8% of 10x Genomics shares are held by institutional investors. Comparatively, 63.0% of Bio-Rad Laboratories shares are held by institutional investors. 13.3% of 10x Genomics shares are held by company insiders. Comparatively, 27.5% of Bio-Rad Laboratories shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares 10x Genomics and Bio-Rad Laboratories' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
10x Genomics$245.89 million86.09$-31,250,000.00($0.80)-243.30
Bio-Rad Laboratories$2.31 billion7.78$1.76 billion$7.0685.35

Bio-Rad Laboratories has higher revenue and earnings than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than Bio-Rad Laboratories, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings for 10x Genomics and Bio-Rad Laboratories, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
10x Genomics01702.88
Bio-Rad Laboratories00303.00

10x Genomics currently has a consensus target price of $181.4444, suggesting a potential downside of 6.78%. Bio-Rad Laboratories has a consensus target price of $700.00, suggesting a potential upside of 16.17%. Given Bio-Rad Laboratories' stronger consensus rating and higher probable upside, analysts clearly believe Bio-Rad Laboratories is more favorable than 10x Genomics.

Profitability

This table compares 10x Genomics and Bio-Rad Laboratories' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
10x Genomics-51.27%-19.98%-14.38%
Bio-Rad Laboratories147.91%3.77%2.74%

Summary

Bio-Rad Laboratories beats 10x Genomics on 10 of the 14 factors compared between the two stocks.


10x Genomics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Illumina logo
ILMN
Illumina
1.6$403.37+0.1%$58.85 billion$3.54 billion93.59Analyst Report
Insider Selling
Agilent Technologies logo
A
Agilent Technologies
1.8$131.91+0.9%$40.19 billion$5.34 billion57.35
Mettler-Toledo International logo
MTD
Mettler-Toledo International
1.3$1,222.41+1.3%$28.51 billion$3.01 billion51.43
Waters logo
WAT
Waters
1.3$307.14+1.0%$19.06 billion$2.41 billion38.25
Avantor logo
AVTR
Avantor
1.8$31.73+0.7%$18.24 billion$6.04 billion264.42
Bio-Rad Laboratories logo
BIO
Bio-Rad Laboratories
1.5$602.57+1.7%$17.98 billion$2.31 billion5.16News Coverage
BIO.B
Bio-Rad Laboratories
0.7$579.38+0.0%$17.28 billion$2.31 billion4.96
PerkinElmer logo
PKI
PerkinElmer
1.9$133.39+1.4%$14.95 billion$2.88 billion36.25
Bruker logo
BRKR
Bruker
1.9$68.61+1.7%$10.40 billion$2.07 billion67.27Gap Up
Coherent logo
COHR
Coherent
1.5$265.56+0.6%$6.50 billion$1.23 billion-15.45
Pacific Biosciences of California logo
PACB
Pacific Biosciences of California
1.6$32.16+4.1%$6.21 billion$90.89 million-114.85News Coverage
Gap Down
Berkeley Lights logo
BLI
Berkeley Lights
1.4$47.24+3.9%$3.13 billionN/A0.00
Quanterix logo
QTRX
Quanterix
1.2$66.12+0.5%$2.40 billion$56.73 million-58.51Insider Selling
News Coverage
Bionano Genomics logo
BNGO
Bionano Genomics
0.9$7.29+3.3%$2.03 billion$10.13 million-3.84Analyst Upgrade
Analyst Revision
News Coverage
Accelerate Diagnostics logo
AXDX
Accelerate Diagnostics
1.8$8.87+2.1%$543.08 million$9.30 million-6.08
Fluidigm logo
FLDM
Fluidigm
1.8$4.60+2.4%$342.92 million$117.24 million-6.87
EyePoint Pharmaceuticals logo
EYPT
EyePoint Pharmaceuticals
1.4$10.01+1.2%$287.70 million$20.36 million-2.94
Harvard Bioscience logo
HBIO
Harvard Bioscience
1.8$6.53+0.3%$260.06 million$116.18 million-36.28Analyst Downgrade
Precipio logo
PRPO
Precipio
1.3$2.05+3.4%$37.17 million$3.13 million0.00
Astrotech logo
ASTC
Astrotech
0.5$1.47+5.4%$36.16 million$490,000.00-1.20High Trading Volume
HTG Molecular Diagnostics logo
HTGM
HTG Molecular Diagnostics
1.1$4.96+2.6%$30.82 million$19.20 million-1.32
This page was last updated on 4/12/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.